Serious adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Intralesional steroid injection plus adjunctive treatment showed no clear difference in maximal mouth opening (interincisal distance) compared with intralesional steroid injection alone (low certainty).
2 findings from 1 review
Outcomes ( · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with Peyronie's disease (stable phase)
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes mortality at maximal compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes cancer‐related mortality at maximal compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe postpartum haemorrhage · pregnant women giving birth in non‐facility settings
It is very uncertain whether prophylactic oxytocin injection (delivered by community health… changes severe postpartum haemorrhage (> 1000 mL) [ compared with control (no injection) (very low certainty).
1 finding from 1 review
Severe maternal morbidity · pregnant women giving birth in non‐facility settings
1 finding from 1 review
Maternal death · pregnant women giving birth in non‐facility settings
1 finding from 1 review
Postpartum haemorrhage · pregnant women giving birth in non‐facility settings
Prophylactic oxytocin injection (delivered by community health… may leads to lower postpartum haemorrhage (PPH greater or equal to 500 mL) [ compared with control (no injection) (low certainty).
2 findings from 1 review
Maternal transfer or referral to a health facility · pregnant women giving birth in non‐facility settings
Prophylactic oxytocin injection (delivered by community health… showed no clear difference in transfer or referral to health facility [ compared with control (no injection) (low certainty).
1 finding from 1 review
Stillbirth · pregnant women giving birth in non‐facility settings
Prophylactic oxytocin injection (delivered by community health… showed no clear difference in stillbirths [ compared with control (no injection) (low certainty).
1 finding from 1 review
Early infant death (0‐3 days) [ · pregnant women giving birth in non‐facility settings
Prophylactic oxytocin injection (delivered by community health… showed no clear difference in early infant death (0‐3 days) [ compared with control (no injection) (low certainty).
1 finding from 1 review